Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review Omar Abdihamid 1 , Abeid Omar 2 and Tibera Rugambwa 3 1 Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, Peoples Republic of China 2 Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Alexandria University, Champlion Street, Alazarita, Alexandria 21131, Egypt 3 Department of Internal Medicine, Mbeya Zonal Referral Hospital, Mbeya 419, Tanzania Abstract Immune checkpoint inhibitors (ICIs) have increased modern anticancer armamentarium portfolios, with 15%60% of cancer patients deriving clinical benefit while others progress, including some occurrences of accelerated progressions
Notably, acylcarnitine from renal cancer may act to reduce the inflammatory response, providing a mechanism by which these cells are able to evade immune surveillance [59]
In here, we estimated the percentage of ground glass lesions with or without consolidation by applying a classification criteria scale as: (1) less than 25%
doi: 10.1016/j.jare.2024.11.017
Offer End In: 160.00Add to cart Adults Food & Allergens food intolerance test uk plus whole-body screening Adults Food & Allergens food intolerance test uk plus whole-body screening Hurry Up
